High-throughput technology that enables sequencing depth for colorectal CA

高通量技术可实现结直肠 CA 深度测序

基本信息

批准号：
8333344
负责人：
G. Mike Makrigiorgos
金额：
$ 10.99万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-15 至 2014-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8333344
关键词：
Admixture Alleles Cancer Etiology Cancer Patient Cell Line Clinical Clinical Oncology Colon Carcinoma Colonic Neoplasms Colorectal DNA Dana-Farber Cancer Institute Data Detection Development Devices Early Diagnosis Emerging Technologies Ensure Fingerprint Generations Genes Genome Heterogeneity Individual Link Liquid substance Low Prevalence Malignant Neoplasms Methods Minority Molecular Molecular Profiling Mutate Mutation Neoplasm Metastasis Operative Surgical Procedures Patients Pharmaceutical Preparations Plasma Positioning Attribute Predictive Value Prevalence Probability Procedures Public Health Radiation therapy Radio Reaction Reagent Resistance Role Sampling Screening procedure Solutions Somatic Mutation Specimen Speed Steam System Technology Temperature Testing Time cancer therapy cancer type chemotherapy clinical practice clinically relevant clinically significant cost cost effective design flexibility follow-up high throughput screening high throughput technology interest mutant nano nanoDroplet next generation novel outcome forecast prevent prognostic research study response tumor

项目摘要

DESCRIPTION (provided by applicant): With the advent of second generation sequencing (SGS), for the first time there is a truly viable possibility of sequencing a substantial portion of an individual cancer patient's genome within a short time period and at relatively low cost, thus detecting mutations that can have prognostic or predictive value, or can serve as a fingerprint for tumor follow-up in a particular patient. However, there is still a missing link in providing a truly reliable identification of mutation fingerprints in patient tumor samples, as clinically-relevant mutations in tumors with heterogeneity, stromal contamination or in bodily fluids is problematic due to admixture with wild type alleles and can still be missed. And yet, the clinical significance of identifying these low-level mutation fingerprints is major in several situations as frequently these are the mutations that confer resistance, offer prognostic and predictive information and that would be useful for treatment follow-up. Unfortunately the new sequencing technologies 'lose steam' when it comes to detecting low-level mutations, and for SGS currently it's either deep sequencing or high-throughput capability, but not both. Thus integration of SGS with clinical practice cannot be effectively exploited. We developed Co-amplification at Lower Denaturation temperature (COLD-PCR), a new form of PCR that amplifies preferentially the minority alleles from mixtures of wild type and mutation-containing sequences, irrespective of where the mutation lies, providing a strong enrichment of the mutated sequences during PCR. We propose to establish massively-parallel COLD-PCR to enrich mutant sequences prior to their screening via SGA (Illumina), thus enabling 'deep' sequencing while also retaining high-throughput capability. To enable massively-parallel COLD-PCR, a micro-fluidic device that dispenses DNA and PCR reagents within individual nano-droplets (RainDance") prior to PCR will be adapted to perform COLD-PCR in millions of separate nano- reactions simultaneously. The novel combination of technologies will be used to identify mutational fingerprints in tumors from 20 colon cancer patients, including low-level mutations, and then follow these fingerprints in plasma in the course of radio-chemo-therapy, to provide a molecular surrogate to therapy response. The proposed use of Novel Transformative Emerging Technologies is also applicable to other types of cancer and provides a solution bridging the gap in technology and enabling SGS to be applied to clinical oncology practice. Therefore relevance to Public Health is high.

描述（由申请人提供）：随着第二代测序（SGS）的出现，第一次真正有可能在短时间内以相对较低的成本对个体癌症患者基因组的大部分进行测序，从而检测具有预后或预测价值的突变，或者可以作为特定患者肿瘤随访的指纹。然而，在提供患者肿瘤样本中突变指纹的真正可靠的鉴定方面仍然存在缺失的环节，因为异质性肿瘤、基质污染或体液中的临床相关突变由于与野生型等位基因的混合而存在问题，并且仍然可以被错过。然而，在多种情况下，识别这些低水平突变指纹的临床意义非常重要，因为这些突变通常会产生耐药性，提供预后和预测信息，并且对于治疗随访很有用。不幸的是，新的测序技术在检测低水平突变时“失去了动力”，对于 SGS 目前来说，它要么是深度测序，要么是高通量能力，但不能两者兼而有之。因此，SGS 与临床实践的结合无法得到有效利用。我们开发了较低变性温度下的共扩增 (COLD-PCR)，这是一种新的 PCR 形式，它优先从野生型和含有突变的序列的混合物中扩增少数等位基因，无论突变位于何处，从而提供了强有力的富集PCR 过程中的突变序列。我们建议在通过 SGA (Illumina) 筛选之前建立大规模并行 COLD-PCR 来富集突变序列，从而实现“深度”测序，同时保留高通量能力。为了实现大规模并行的 COLD-PCR，在 PCR 之前将 DNA 和 PCR 试剂分配到单个纳米液滴中的微流体装置 (RainDance") 将适用于同时在数百万个单独的纳米反应中执行 COLD-PCR。新型技术组合将用于识别 20 名结肠癌患者肿瘤中的突变指纹，包括低水平突变，然后在放化疗过程中追踪血浆中的这些指纹，以提供分子拟议的新型变革性新兴技术的使用也适用于其他类型的癌症，并提供了一种弥合技术差距的解决方案，并使 SGS 能够应用于临床肿瘤学实践，因此与公共卫生具有很高的相关性。